Progress on Research of 5-Lipoxygenase in Alzheimer’s Disease

doi:10.3969/j.issn.2095-1396.2016.05.006

Abstract

Abstract: 5-lipoxygenase plays a key role in catalyzing the conversion of arachidonic acid （AA） to 5-hydroperoxy-6，8，11，14-eicosatetraenoic acid （5-HPETE），which can then be metabolized into different leukotrienes （LTs）. The recently studies have shown that 5-lipoxygenase is involved in the pathophysiology of Alzheimer’s disease. Inhibition of 5-lipoxygenase decreases amyloid β peptide （Aβ） and tau hyperphosphorylation，mitigates neuroinflammation，regulates synaptic function and ameliorates cognitive disorders in Alzheimer’s disease. In this review，we will summarize studies of 5-lipoxygenase in Alzheimer’s disease pathogenesis.

Key words: Alzheimer&, rsquo, s disease, 5-lipoxygenase, &, beta, -amyloid peptide, tau, neuroinflammation

DU Guan-tao，ZHANG Chun-teng，HONG Hao. Progress on Research of 5-Lipoxygenase in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2016, 6(5): 39-44.

References

[1] Danubia Bonfanti Dos Santos, Dirleise Colle, Eduardo Luiz Gasnhar Moreira, et al. Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice [J]. Neuroscience, 2015, 284: 590-600.

[2] Thomas Wisniewski, Fernando Goñi. Immunotherapeutic approaches for Alzheimer’s disease [J]. Neuron, 2015, 85(6): 1162-1176.

[3] Yash B Joshi, Domenico Praticò. The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype [J]. Frontiers in Cellular Neuroscience, 2015, 8: 436.

[4] Phillip F Giannopoulos, Yash B Joshi, Domenico Praticò. Novel lipid signaling pathways in Alzheimer's disease pathogenesis [J]. Biochem Pharmacol, 2014, 88(4): 560-564.

[5] Omidreza Firuzi, Zhuo Jia-min, Cinzia M Chinnici, et al. 5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer’s disease [J]. FASEB J, 2008, 22(4): 1169-1178.

[6] Milos D Ikonomovic, Eric E Abrahamson, Tolga Uz, et al. Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease [J]. J Histochem Cytochem, 2008, 56(12): 1065-1073.

[7] Elvira Valera, Richard Dargusch, Pamela A Maher, et al. Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease [J]. J Neuroscience the Official J Society for Neuroscience, 2013, 33(22):10512-10525.

[8] Chu Jin, Phillip F Giannopoulos, Carolina Ceballos-Diaz, et al. 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of alzheimer disease [J]. Ann Neurol, 2012, 72(3): 442-454.

[9] Olof P Rådmark. The molecular biology and regulation of 5-lipoxygenase [J]. Am J Respir Crit Care Med, 2000, 161(1): S11-15.

[10] Chu Jin, Domenico Praticò. The 5-lipoxygenase as a common pathway for pathological brain and vascular aging [J]. Cardiovasc Psychiatry Neurol, 2009, 2009: 174657. doi: 10.1155/2009/174657.

[11] Kausik Bishayee, Anisur Rahman Khudabukhsh. 5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy [J]. Acta Biochimica Et Biophysica Sinica, 2013, 45(9): 709-719.

[12] Rakesh Kumar Singh, Suman Gupta, Sunanda Dastidar, et al. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics [J]. Pharmacology, 2010, 85(6): 336-349.

[13] Takehiko Yokomizo, Takashi Izumi, Takao Shimizu. Leukotriene B4: metabolism and signal transduction [J]. Arch Biochem Biophys, 2001, 385(2): 231-241.

[14] Tang Su-su, Wang Xiao-yun, Hong Hao, et al. Leukotriene D4 induces cognitive impairment through enhancement of CysLT1R-mediated amyloid-β generation in mice [J]. Neuropharmacology, 2013, 65: 182-192.

[15] Milos D Ikonomovic, Eric E Abrahamson, Tolga Uz, et al. Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease [J]. J Histochem Cytochem, 2008, 56(12): 1065-1073.与6重复

[16] Elvira Valera, Richard Dargusch, Pamela A Maher, et al. Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease [J]. J Neurosci, 2013, 33(25): 10512-10525.与7重复

[17] Cinzia M Chinnici, Yao Yue-mang, Domenico Praticò. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old [J]. Neurobiol Aging, 2007, 28(9): 1457-1462.

[18] Omidreza Firuzi, Zhuo Jia-min, Cinzia M Chinnici, et al. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease [J]. FASEB J, 22(4): 1169-1178.

[19] Florinda Listì, Calogero Caruso, Domenico Lio, et al. Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics [J]. J Alzheimers Disease Jad, 2010, 19(2): 551-557.

[20] Phillip F Giannopoulos, Yash B Joshi, Domenico Praticò. Novel lipid signaling pathways in Alzheimer's disease pathogenesis [J]. Biochem Pharmacol, 2014, 88(4): 560-564.与4重复

[21] Chu Jin, Domenico Praticò. 5-lipoxygenase as an endogenous modulator of amyloid β formation in vivo [J]. Ann Neurol, 2011, 69(1): 34–46.

[22] Chu Jin, Domenico Praticò. Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase [J]. Am J Pathol, 2011, 178(4): 1762-1769.

[23] Chu Jin, Li Jin-guo, Domenico Praticò. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles [J]. PLoS One, 2013, 8(8): e70991.

[24] Chu Jin, Domenico Praticò. The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target [J]. Brain Res Bull, 2016, 126(Pt 2): 207-212.

[25] Chu Jin, Li Jian-guo, Nicholas E Hoffman, et al. Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidence [J]. Scientific Reports, 2015, 5:11086.

[26] Chu Jin, Li Jian-guo, Yash B Joshi, et al. Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer’s disease [J]. Biol Psychiatry, 2015, 77(8):720-728.

[27] Ren Qing-guo, Liao Xiao-mei, Chen Xiao-qian, et al. Effects of tau phosphorylation on proteasome activity [J]. FEBS Lett, 2007, 581(7): 1521-1528.

[28] Liu Gong-ping, Wei Wei, Zhou Xin, et al. I(2)(PP2A) regulates p53 and Akt correlatively and leads the neurons to abort apoptosis [J]. Neurobiol Aging, 2012, 33(2): 254-264.

[29] Chu Jin, Li Jian-guo, Carolina Ceballos-Diaz, et al. The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence [J]. Biol Psychiatry, 2013, 74(5): 321-328.

[30] Antonio Di Meco, Elisabetta Lauretti, Alana N Vagnozzi, et al. Zileuton restores memory impairments and reverses amyloid and tau pathology in aged AD mice [J]. Neurobiol Aging, 2014, 35(11): 2458-2464.

[31] Helmut Kettenmann, Frank Kirchhoff, Alexei Verkhratsky. Microglia: new roles for the synaptic stripper [J]. Neuron, 2013, 77(1):10-18.

[32] Uwe-Karsten Hanisch, Helmut Kettenmann. Microglia: active sensor and versatile effector cells in the normal and pathologic brain [J]. Nat Neurosci, 2007, 10(11): 1387-1394.

[33] Helmut Kettenmann, Uwe-Karsten Hanisch, Mami Noda M, et al. Physiology of microglia[J]. Physiol Rev, 2011, 91(2): 461-553.

[34] Patrick L Mcgeer, Edith G M Mcgeer. Targeting microglia for the treatment of Alzheimer’s disease [J]. Glia, 2015, 19(4): 497-506.

[35] Olof Rådmark, Bengt Samuelsson. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis [J]. Biochem Biophys Res Commun, 2010, 396(1): 105-110.

[36] Yash B Joshi, Phillip F Giannopoulos, Chu Jin, et al. Modulation of lipopolysaccharide-induced memory insult, γ-secretase, and neuroinflammation in triple transgenic mice by 5-lipoxygenase [J]. Neurobiol Aging, 2014, 35(5): 1024-1031.

[37] Jin Chu, Domenico Praticò. Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer’s disease mouse model [J]. J Neuroinflammation, 2012, 9: 127.

[38] Ashok Kumar, Sorabh Sharma, Ashwani Prashar, et al. Effect of licofelone--a dual COX/5-LOX inhibitor in intracerebroventricular streptozotocin-induced behavioral and biochemical abnormalities in rats [J]. J Mol Neurosci, 2015, 55(3): 749-759.

[39] Murtishaw A S, Heaney C F, Bolton M M, et al. Effect of acute lipopolysaccharide-induced inflammation in intracerebroventricular-streptozotocin injected rats [J]. Neuropharmacology, 2015, 101: 110-122.

[40] Pradip K Kamat, Anuradha Kalani, Shivika Rai, et al. Streptozotocin intracerebroventricular-induced neurotoxicity and brain insulin resistance: a therapeutic intervention for treatment of sporadic Alzheimer's disease (sAD)-like pathology [J]. Mol Neurobiol, 2016, 53(7): 4548-4562.

[41] Lai Jine, Hu Meng, Wang Hao, et al. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice [J]. Neuropharmacology, 2014, 79: 707-714.

[42] Zhang Chun-teng, Lin Jing-ran, Wu Feng, et al. Montelukast ameliorates streptozotocin-induced cognitive impairment and neurotoxicity in mice [J]. Neurotoxicology, 2016, 57: 214-222.

[43] Julia Marschallinger, Iris Schäffner, Barbara Klein, et al. Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug [J]. Nature Communications, 2015, 6: 8466.

[44] Chu Jin, Phillip F Giannopoulos, Carolina Ceballos-Diaz, et al. Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice [J]. Molecular Neurodegeneration, 2012, 7(1): 1.

[45] Chu J, Giannopoulos PF, Ceballos-Diaz C, et al. 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of alzheimer disease [J]. Ann Neurol, 2012, 72(3): 442-454.与8重复

[46] Phillip Fotios Giannopoulos, Chu Jin, Yash B Joshi, et al. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer’s disease [J]. Mol Psychiatry, 2013, 19(4): 511-518.